{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:16:58Z","timestamp":1779182218572,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40258-018-0432-4","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T22:09:28Z","timestamp":1537999768000},"page":"77-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States"],"prefix":"10.1007","volume":"17","author":[{"given":"Fang","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne G.","family":"Wheaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina M.","family":"Rabarison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet B.","family":"Croft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"432_CR1","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.15585\/mmwr.mm6542a3","volume":"65","author":"JM Dahlhamer","year":"2016","unstructured":"Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged\u2009\u226518 Years\u2014United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:1166\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"432_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.crohns.2007.06.005","volume":"1","author":"S Ghosh","year":"2007","unstructured":"Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn\u2019s and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis. 2007;1:10\u201320.","journal-title":"J Crohns Colitis."},{"key":"432_CR3","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/ibd.20388","volume":"14","author":"A Vidal","year":"2008","unstructured":"Vidal A, Gomez-Gil E, Sans M, et al. Health-related quality of life in inflammatory bowel disease patients: the role of psychopathology and personality. Inflamm Bowel Dis. 2008;14:977\u201383.","journal-title":"Inflamm Bowel Dis"},{"key":"432_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.crohns.2012.02.014","volume":"7","author":"B Bokemeyer","year":"2013","unstructured":"Bokemeyer B, Hardt J, Huppe D, et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis. 2013;7:355\u201368.","journal-title":"J Crohns Colitis."},{"key":"432_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/ecco-jcc\/jjv190","volume":"10","author":"V Annese","year":"2016","unstructured":"Annese V, Duricova D, Gower-Rousseau C, Jess T, Langholz E. Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the Epidemiology Committee of ECCO. J Crohns Colitis. 2016;10:216\u201325.","journal-title":"J Crohns Colitis."},{"key":"432_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.15585\/mmwr.mm6614a1","volume":"66","author":"CA Malarcher","year":"2017","unstructured":"Malarcher CA, Wheaton AG, Liu Y, et al. Hospitalizations for Crohn\u2019s disease\u2014United States, 2003\u20132013. MMWR Morb Mortal Wkly Rep. 2017;66:377\u201381.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"432_CR7","unstructured":"Crohn\u2019s & Colitis Foundation. The facts about inflammatory bowel disease. 2014; \n                    http:\/\/www.crohnscolitisfoundation.org\/assets\/pdfs\/updatedibdfactbook.pdf\n                    \n                  . Accessed 29 September 2017."},{"key":"432_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/gastro\/gou087","volume":"3","author":"AC Moss","year":"2015","unstructured":"Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep. 2015;3:63\u20138.","journal-title":"Gastroenterol Rep."},{"key":"432_CR9","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","volume":"145","author":"AD Frolkis","year":"2013","unstructured":"Frolkis AD, Dykeman J, Negron ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145:996\u20131006.","journal-title":"Gastroenterology"},{"key":"432_CR10","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/gut.2010.234617","volume":"60","author":"G Bouguen","year":"2011","unstructured":"Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn\u2019s disease: what is the actual risk? Gut. 2011;60:1178\u201381.","journal-title":"Gut"},{"key":"432_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11605-010-1396-3","volume":"15","author":"AN Ananthakrishnan","year":"2011","unstructured":"Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267\u201376.","journal-title":"J Gastrointest Surg."},{"key":"432_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/ajg.2014.45","volume":"109","author":"MK Vester-Andersen","year":"2014","unstructured":"Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol. 2014;109:705\u201314.","journal-title":"Am J Gastroenterol"},{"key":"432_CR13","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1053\/j.gastro.2008.09.012","volume":"135","author":"MD Kappelman","year":"2008","unstructured":"Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn\u2019s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907\u201313.","journal-title":"Gastroenterology"},{"key":"432_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10198-010-0281-z","volume":"12","author":"A Prenzler","year":"2011","unstructured":"Prenzler A, Bokemeyer B, von der Schulenburg JM, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ. 2011;12:273\u201383.","journal-title":"Eur J Health Econ."},{"key":"432_CR15","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1097\/JOM.0b013e318181b8ca","volume":"50","author":"TB Gibson","year":"2008","unstructured":"Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn\u2019s disease and ulcerative colitis. J Occup Environ Med. 2008;50:1261\u201372.","journal-title":"J Occup Environ Med"},{"issue":"385\u2013392","key":"432_CR16","first-page":"e382","volume":"15","author":"J Limsrivilai","year":"2017","unstructured":"Limsrivilai J, Stidham RW, Govani SM, Waljee AK, Huang W, Higgins PD. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017;15(385\u2013392):e382.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"432_CR17","unstructured":"Agency for Healthcare Research & Quality. Data innovations\u2014ICD-10-CM\/PCS resources. 2017; \n                    https:\/\/www.hcup-us.ahrq.gov\/datainnovations\/icd10_resources.jsp\n                    \n                  . Accessed 3 January 2018."},{"key":"432_CR18","unstructured":"Agency for Healthcare Research & Quality. Nationwide inpatient sample redesign report. 2018; \n                    https:\/\/www.hcup-us.ahrq.gov\/db\/nation\/nis\/reports\/NISRedesignFinalReport040914.pdf\n                    \n                  . Accessed 3 January 2018."},{"key":"432_CR19","unstructured":"IBM Watson Health. Putting research data into your hands with the MarketScan databases. 2018; \n                    http:\/\/truvenhealth.com\/markets\/state-and-medicaid\/products\/data-and-tools\/marketscan-database\n                    \n                  . Accessed 12 January 2018."},{"key":"432_CR20","unstructured":"Agency for Healthcare Research & Quality. Overview of the national (Nationwide) inpatient sample (NIS). 2017; \n                    https:\/\/www.hcup-us.ahrq.gov\/nisoverview.jsp\n                    \n                  . Accessed 2 October 2017."},{"key":"432_CR21","unstructured":"Truven Health Analytics. Commercial claims and encounters Medicare supplemental. 2017; \n                    https:\/\/marketscan.truvenhealth.com\/marketscanuniversity\/userguide\/2015%20MarketScanCCAE-MDCRUserGuide.pdf\n                    \n                  ."},{"key":"432_CR22","unstructured":"Agency for Healthcare Research & Quality. Cost-to-charge ratio files. 2017; \n                    https:\/\/www.hcup-us.ahrq.gov\/db\/state\/costtocharge.jsp#overview\n                    \n                  . Accessed 3 October 2017."},{"key":"432_CR23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/MLR.0000000000000410","volume":"53","author":"C Peterson","year":"2015","unstructured":"Peterson C, Xu L, Florence C, Grosse SD, Annest JL. Professional fee ratios for US hospital discharge data. Med Care. 2015;53:840\u20139.","journal-title":"Med Care"},{"key":"432_CR24","unstructured":"Statistics Bureau of Labor. Databases, tables and calculators by subject. 2017; \n                    https:\/\/data.bls.gov\/timeseries\/CUUR0000SA0\n                    \n                  ."},{"key":"432_CR25","unstructured":"Agency for Healthcare Research & Quality. Elixhauser comorbidity software, version 3.7. 2017; \n                    https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/comorbidity\/comorbidity.jsp\n                    \n                  . Accessed 12 January 2018."},{"key":"432_CR26","unstructured":"Agency for Healthcare Research & Quality. Overview of disease severity measures disseminated with Nationwide Inpatient Sample (NIS) and Kids\u2019 Inpatient Database (KID). \n                    https:\/\/www.hcup-us.ahrq.gov\/db\/nation\/nis\/OverviewofSeveritySystems.pdf\n                    \n                  . Accessed 3 October 2007."},{"key":"432_CR27","unstructured":"Agency for Healthcare Research & Quality. NIS description of data elements: HOSP_BEDSIZE\u2014bedsize of hospital. 2008; \n                    https:\/\/www.hcup-us.ahrq.gov\/db\/vars\/hosp_bedsize\/nisnote.jsp\n                    \n                  . Accessed 3 January 2018."},{"key":"432_CR28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/MIB.0000000000001068","volume":"23","author":"GC Nguyen","year":"2017","unstructured":"Nguyen GC, Murthy SK, Bressler B, et al. Quality of care and outcomes among hospitalized inflammatory bowel disease patients: a multicenter retrospective study. Inflamm Bowel Dis. 2017;23:695\u2013701.","journal-title":"Inflamm Bowel Dis"},{"key":"432_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1572-0241.2000.01845.x","volume":"95","author":"CN Bernstein","year":"2000","unstructured":"Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 2000;95:677\u201383.","journal-title":"Am J Gastroenterol"},{"key":"432_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00004836-199206000-00009","volume":"14","author":"JW Hay","year":"1992","unstructured":"Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992;14:309\u201317.","journal-title":"J Clin Gastroenterol"},{"key":"432_CR31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.15585\/mmwr.mm6706a4","volume":"67","author":"F Xu","year":"2018","unstructured":"Xu F, Dahlhamer JM, Zammitti EP, Wheaton AG, Croft JB. Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease\u2014United States, 2015 and 2016. MMWR Morb Mortal Wkly Rep. 2018;67:190\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"432_CR32","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/MEG.0000000000000891","volume":"29","author":"C Bahler","year":"2017","unstructured":"Bahler C, Schoepfer AM, Vavricka SR, Brungger B, Reich O. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol. 2017;29:916\u201325.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"432_CR33","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.3748\/wjg.v17.i22.2723","volume":"17","author":"ALS Rom\u00e1n","year":"2011","unstructured":"Rom\u00e1n ALS, Mu\u00f1oz F. Comorbidity in inflammatory bowel disease. World J Gastroenterol. 2011;17:2723\u201333.","journal-title":"World J Gastroenterol"},{"key":"432_CR34","doi-asserted-by":"publisher","first-page":"13863","DOI":"10.3748\/wjg.v20.i38.13863","volume":"20","author":"P Zezos","year":"2014","unstructured":"Zezos P, Kouklakis G, Saibil F. Inflammatory bowel disease and thromboembolism. World J Gastroenterol. 2014;20:13863\u201378.","journal-title":"World J Gastroenterol"},{"key":"432_CR35","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/157016112801784495","volume":"10","author":"A Stadnicki","year":"2012","unstructured":"Stadnicki A. Involvement of coagulation and hemostasis in inflammatory bowel diseases. Curr Vasc Pharmacol. 2012;10:659\u201369.","journal-title":"Curr Vasc Pharmacol"},{"key":"432_CR36","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/ibd.21468","volume":"17","author":"K Oikonomou","year":"2011","unstructured":"Oikonomou K, Kapsoritakis A, Eleftheriadis T, Stefanidis I, Potamianos S. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1034\u201345.","journal-title":"Inflamm Bowel Dis"},{"key":"432_CR37","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/01.MIB.0000166932.66853.fd","volume":"11","author":"E Hait","year":"2005","unstructured":"Hait E, Bousvaros A, Grand R. Pediatric inflammatory bowel disease: what children can teach adults. Inflamm Bowel Dis. 2005;11:519\u201327.","journal-title":"Inflamm Bowel Dis"},{"key":"432_CR38","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/ibd.21878","volume":"18","author":"CN Bernstein","year":"2012","unstructured":"Bernstein CN, Longobardi T, Finlayson G, Blanchard JF. Direct medical cost of managing IBD patients: a Canadian population-based study. Inflamm Bowel Dis. 2012;18:1498\u2013508.","journal-title":"Inflamm Bowel Dis"},{"key":"432_CR39","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ibd.22986","volume":"19","author":"JL Sewell","year":"2013","unstructured":"Sewell JL, Velayos FS. Systematic review: the role of race and socioeconomic factors on IBD healthcare delivery and effectiveness. Inflamm Bowel Dis. 2013;19:627\u201343.","journal-title":"Inflamm Bowel Dis"},{"key":"432_CR40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.crohns.2013.09.001","volume":"8","author":"GC Nguyen","year":"2014","unstructured":"Nguyen GC, Chong CA, Chong RY. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohns Colitis. 2014;8:288\u201395.","journal-title":"J Crohns Colitis."},{"key":"432_CR41","volume-title":"Overview of hospital stays in the United States, 2012: Statistical Brief #180. Healthcare Cost and Utilization Project (HCUP) statistical briefs","author":"AJ Weiss","year":"2006","unstructured":"Weiss AJ, Elixhauser A. Overview of hospital stays in the United States, 2012: Statistical Brief #180. Healthcare Cost and Utilization Project (HCUP) statistical briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006."},{"key":"432_CR42","doi-asserted-by":"publisher","first-page":"e587","DOI":"10.7717\/peerj.587","volume":"2","author":"MD Park","year":"2014","unstructured":"Park MD, Bhattacharya J, Park K. Differences in healthcare expenditures for inflammatory bowel disease by insurance status, income, and clinical care setting. PeerJ. 2014;2:e587.","journal-title":"PeerJ."},{"key":"432_CR43","volume-title":"Inpatient stays in rural hospitals, 2007: Statistical Brief #85. Healthcare Cost and Utilization Project (HCUP) statistical briefs","author":"E Stranges","year":"2006","unstructured":"Stranges E, Holmquist L, Andrews RM. Inpatient stays in rural hospitals, 2007: Statistical Brief #85. Healthcare Cost and Utilization Project (HCUP) statistical briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006."},{"key":"432_CR44","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/gutjnl-2011-301397","volume":"61","author":"CN Bernstein","year":"2012","unstructured":"Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B. Hospitalisations and surgery in Crohn\u2019s disease. Gut. 2012;61:622\u20139.","journal-title":"Gut"},{"key":"432_CR45","doi-asserted-by":"publisher","first-page":"e0185500","DOI":"10.1371\/journal.pone.0185500","volume":"12","author":"N Pillai","year":"2017","unstructured":"Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conentional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12:e0185500.","journal-title":"PLoS One"},{"key":"432_CR46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","volume":"12","author":"S Danese","year":"2015","unstructured":"Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537\u201345.","journal-title":"Nat Rev Gastroenterol Hepatol."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-018-0432-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-018-0432-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-018-0432-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T20:10:05Z","timestamp":1569528605000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-018-0432-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["432"],"URL":"https:\/\/doi.org\/10.1007\/s40258-018-0432-4","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"assertion":[{"value":"27 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Fang Xu, Yong Liu, Anne G. Wheaton, Kristina M. Rabarison, and Janet B. Croft have no conflict of interest in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}